{
    "nct_id": "NCT04933695",
    "official_title": "A Phase 2, Multicenter, Open-label Study of Sotorasib (AMG 510) in Subjects With Stage IV NSCLC Whose Tumors Harbor a KRAS G12C Mutation in Need of First-line Treatment (CodeBreaK 201)",
    "inclusion_criteria": "* Adult (= or > 18 years old) with NSCLC\n* Untreated Stage IV metastatic disease. Participants who received adjuvant or neoadjuvant anti-tumor therapy are eligible if the adjuvant/neoadjuvant therapy was completed greater than 12 months prior to the development of metastatic stage IV disease\n* Pathologically documented metastatic NSCLC with KRAS G12C mutation (local confirmation)\n* Programmed death-ligand 1 (PD-L1) TPS Score < 1% and/or serine/threonine kinase 11 (STK11) co-mutation (local confirmation)\n* Eastern Cooperative Oncology Group (ECOG) score of 0 or 1\n* No active brain metastases\n* Measurable disease per investigator interpretation using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Mixed small-cell lung cancer and NSCLC histology\n* Myocardial Infarction within 6 months of study Day 1\n* Use of proton-pump inhibitors (PPIs), histamine (H2) receptor antagonists (H2RA), strong inducers of cytochrome P450 (CYP) 3A4 (CYP3A4) or known CYP3A4 sensitive substrates or P-gp substrates\n* Therapeutic or palliative radiation therapy within 2 weeks of study day 1\n* Unable to take oral medication\n* Unable to receive both iodinated contrast for computed tomography (CT) scans and gadolinium contrast for magnetic resonance imagine (MRI) scans",
    "miscellaneous_criteria": ""
}